Chemed Corporation logo CHE - Chemed Corporation

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 3
HOLD 6
SELL 0
STRONG
SELL
0
| PRICE TARGET: $554.00 DETAILS
HIGH: $633.00
LOW: $475.00
MEDIAN: $554.00
CONSENSUS: $554.00
UPSIDE: 6.57%

Stock News

CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporation's Directors and Officers for Breach of Fiduciary Duties – CHE

CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporation's Directors and Officers for Breach of Fiduciary Duties – CHE

NEW YORK--(BUSINESS WIRE)---- $CHE #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Chemed Corporation (NYSE: CHE) failed to manage Chemed in an acceptable manner, breaching their fiduciary duties to Chemed, and whether Chemed and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On August 13, 2026, The Capital Forum released a report alleging t.

Sep 03, 2026 12:00 PM businesswire.com (Hide legal announcements)
CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporation's Directors and Officers for Breach of Fiduciary Duties – CHE

CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporation's Directors and Officers for Breach of Fiduciary Duties – CHE

NEW YORK--(BUSINESS WIRE)---- $CHE #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Chemed Corporation (NYSE: CHE) failed to manage Chemed in an acceptable manner, breaching their fiduciary duties to Chemed, and whether Chemed and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On August 13, 2026, The Capital Forum released a report alleging t.

Aug 20, 2026 04:30 AM businesswire.com (Hide legal announcements)
Chemed Corporation: Why A Spin-Off Could Unlock Its Hidden Value

Chemed Corporation: Why A Spin-Off Could Unlock Its Hidden Value

Chemed Corporation (CHE) receives a Buy rating with a $632/share target, driven by activist pressure for a spin-off to eliminate the conglomerate discount. VITAS has successfully reengineered its patient mix, sharply reducing Medicare Cap penalties and driving 8.8% revenue growth and 18.2% Adjusted EBITDA margin in Q2. Roto-Rooter faces structural margin pressure from rising digital marketing costs, but B2B expansion and operational efficiencies are expected to support future growth.

Aug 05, 2026 02:39 AM seekingalpha.com
Chemed Reports Second-Quarter 2026 Results

Chemed Reports Second-Quarter 2026 Results

CINCINNATI, July 28, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2026, versus the comparable prior-year period. Results for Quarter Ended June 30, 2026 Consolidated operating results: Revenue increased 8.8% to $673.3 million GAAP Diluted Earnings-per-Share (EPS) of $5.13, an increase of 43.7% Adjusted Diluted EPS of $6.06, an increase of 41.9% VITAS segment operating results: Net Patient Revenue of $443.3 million, an increase of 11.9% Average Daily Census (ADC) of 23,687, an increase of 6.1% Admissions of 19,125, an increase of 9.0% Net Income, excluding certain discrete items, of $61.3 million, an increase of 60.5% Adjusted EBITDA, excluding Medicare Cap, of $80.6 million, an increase of 20.6% Adjusted EBITDA margin, excluding Medicare Cap, of 18.2%, an increase of 196-basis points Roto-Rooter segment operating results: Revenue of $229.9 million, an increase of 3.3% Net Income, excluding certain discrete items, of $33.8 million, essentially flat Adjusted EBITDA of $48.5 million, essentially flat Adjusted EBITDA margin of 21.1%, a decline of 77-basis points VITAS VITAS net revenue was $443.3 million in the second quarter of 2026, which is an increase of 11.9% when compared to the prior-year period.

Jul 28, 2026 12:15 PM globenewswire.com

Price Targets